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Available Copy 0 --sporozoite (CS) protein and sporozoite surface protein 2 completely protects against sporozoite challenge. Thus, there are now efforts to develop vaccines that induce CTL against the CS protein and sporozoite surface protein 2. Until recently, it was thought that induction of CTL required production of target proteins within cells, breakdown of the proteins to peptides in the cytoplasm, and transport of the peptides to the cell surface | in combination with class I major histocompatibility complex molecules. It has now been shown that -• immunization with peptides in Freund's complete adjuvant and with soluble protein in liposomes can induce g CTL. To determine whether we could induce CTL against the Plasmodium falciparum CS protein by immunization with soluble protein, BI0.BR mice were immunized intravenously, intraperitoneally, or intramuscularly with a recombinant P. fakiparum CS protein called RLF mixed with the adjuvant DETOX (monophosphoryl lipid A, cell wall skeleton of Mycobacteria phlei, and squalane). Two weeks after the last dose, spleen cells from mice immunized intravenously, but not intraperitoneally or intramuscularly, had peptidespecific, major histocompatibility complex-restricted, CD8+ T-cell-depend-. t cytolytic activity against peptide 368-390 from the 7G8 P.falciparum CS protein. To determine whether the adjuvant was required for induction of the cytolytic activity, mice were immunized with RLF without adjuvant, and similar cytolytic activity was demonstrated. The finding that we could induce CTL by administration of soluble protein without adjuvant markedly broadens the possibilities for vaccinologists working to develop methods of inducing CTL in humans.
Immunization of mice with a recombinant Salmonella sp.
vector vaccines such as a recombinant Salmonella sp. (1), expressing the Plasmodium berghei circurnsporozoite (CS) vaccinia virus (8), or pseudorabies virus (15) . However, in protein (1) and transfected P815 mouse mastocytoma cells the past few years it has been demonstrated that immunizing expressing the P. yoelii CS protein or P. yoelii sporozoite with short lipopeptides (2), ISCOMS (16) , and peptides in surface protein 2 (7) partially protects against malaria. This Freund's complete adjuvant could all induce CTL (11). protective immunity is eliminated by in vivo depletion of
Recently, it has been demonstrated that CTL can be induced CD8÷ T cells, indicating that cytotoxic T lymphocytes by immunization with soluble protein in liposomes (10). (CTL) against these proteins are required for this protection.
We have conducted clinical studies with a malaria protein Furthermore, adoptive transfer of CTL clones against the P. administered with an adjuvant containing monophosphoryl berghei (14) and P. yoelii CS proteins (13, 17) can completely lipid A (MPL), cell wall skeleton (CWS) mycobacteria, and protect against sporozoite challenge, indicating that CTL squalane (12). When compared with aluminum hydroxide, can protect in the absence of other parasite-specific immune this adjuvant (DETOX) improved the antibody response responses. Accordingly, some current human vaccine develagainst the malaria protein (12). The current studies were opment efforts are directed towards induction of CTL undertaken to determine whether immunization of mice with against the P. falciparum CS protein and sporozoite surface a recombinant malaria protein in this adjuvant would induce protein 2.
CTL. Having established that this was the case, we demonInduction of CTL has generally been thought to require strated that immunization with this soluble recombinant transport of peptides from the cytosol into the lumen of the malaria protein induces CTL even without the use of adjuendoplasmic reticulum, where the peptides bind to major vant. histocompatibility complex (MHC) class I heavy chains and are assembled with I3 2 -microglobulin. The bound peptides are transported to the cell surface with MHC class I mole-MATERIALS AND METHODS cules, where they can be recognized by T cells. Until recently, it was thought that the proteins had to be produced Mice. Six-week-old B10.BR (H-2&) mice were purchased inside the cells for them to enter the class I MHC pathway from Jackson Laboratories, Bar Harbor. Maine. The exper--effectively and that this would require recombinant live iments reported herein were conducted according to the principles set forth in the Guide for the Care and Use of Laboratory Animal.
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Immunogen. The CS protein of the 7G8 clone of the P. Corresponding author.
falciparum CS protein includes 412 amino acids. It has a Vot_. 61, 1993
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central repeat region with 37 copies of NANP and 4 copies of so NVDP, a total of 164 amino acids. A recombinant protein in that included the entire P. f'alcipanin CS protein minus 70 these central 164 amino acids was produced, fused to 81 amino acids from the nonstructural protein of influenza A Lt0 268-n90) virus attached at the carboxyl end, and purified so that it could be used to immunize humans. The formulation was greater than 90% pure and met Food and Drug Administration standards for endotoxin levels and DNA content (5). (8) . This region has also been shown to include a CTL epitope for humans (9) . A 23-aminoacid synthetic peptide (KPKDELDYENDIEKKICKMEK CS), including amino acid residues 368 to 390 (Pf CSP Ontario, Canada) was added at a final concentration of 10%. 368-390), and a 20-amino-acid control peptide [Pf CS After 30 min of incubation at 37°C, cells were washed twice (PNAN) 5 ; amino acids 151 to 1701, including five copies of in RPMI 1640 medium (GIBCO, Grand Island, N.Y.) and the major repeat of the P. falcipanim CS protein, were used then used in a chromium release assay. (9) .
Chromium release assay. For in vitro cytotoxicity assays, Effector cells. Mice in each group had received two immu-5,000 chromium-labelled target cells were incubated with nizations. Two weeks after the last immunization, spleen effector cells for 6 h in a final volume of 0.2 ml in 96-well cells were isolated for use as effector cells. Briefly, 5 x 10' round-bottom plates (Costar, Cambridge, Mass.) in triplispleen cells were plated in 24-well tissue culture plates in a cate. Supernatants were harvested by using a Skatron SCS final volume of 2 ml of complete medium (RPMI 1640 system (Skatron Inc., Sterling, Va.), and chromium-51 remedium supplemented with 10% fetal calf serum, L-gluleased in supernatants was measured with a gamma counter tamine 12 mM], 2-mercaptoethanol [5 X 10-5 M], and (Clinnigamma; Pharmacia LKB Nuclear Inc., Gaithersburg, penicillin and streptomycin [50 U/ml each]).
Md.). Maximum chromium-51 release was determined by Stimulator cells. L cells (H-2k) transfected with the DNA lysing target cells with 5% Triton X-100. Percent specific encoding the full-length P. falciparum CS protein (8) were lysis was determined as follows: 100 x [(experimental reused for in vitro stimulation. The transfected L cells (LPf) lease -spontaneous release)/(maximum release -spontawere treated with mitomycin (50 .g/ml), and then 2 x 10' neous release)]. LPf per well were added to 24-well plates that contained 5 x 106 effector cells per well. Cultures were then incubated for RESULTS 5 days at 37°C in 5% CO 2 .
Target cells. LPf (H-2k), untransfected L cells (H-2'), and
Immunization of mice with RLF-DETOX induces CTL P815 mouse mastocytoma cells (H-2d) were used as target activity. To establish a baseline for the assays, B10.BR mice cells. Eighteen hours before a CTL assay, 106 L cells or P815
were immunized with a recombinant vaccinia virus expresscells were incubated in the presence of 100 gg of peptide per ing the P. falciparum CS protein (8) . The spleen cells were ml and 100 V.Ci of sodium chromate (Dupont-New England stimulated with LPf, and either chromium-labelled LPf or Nuclear Inc., Boston, Mass.) in 2 ml of medium. LPf, 106, peptide-pulsed, chromium-labelled L cells were used as were incubated in 2 ml of medium with 100 i.Ci of sodium targets. LPf were somewhat better as targets than were chromate only.
peptide Pf CSP 368-390-pulsed targets, but both were good Depletion of T lymphocytes. In vitro depletion of CD4' and targets for CTL (Fig. 1) . When B10.BR mice were immu-CD8÷ T lymphocytes from the effector cells was done with nized with two doses of RLF-DETOX intraperitoneally or anti-CD4 monoclonal antibody GK 1.5 (rat immunoglobulin intramuscularly no CTL could be identified (data not G subclass 2b) (3) and anti-CD8 monoclonal antibody 19/178 shown). When the mice were immunized with two i.v. doses (mouse immunoglobulin G subclass 2a) (6). Briefly, effector of RLF-DETOX, CTL against peptide 368-390 were identicells were incubated with anti-CD4 or anti-CD8 monoclonal fled (Fig. 2a) . This response was antigen specific, MHC antibodies for 30 min. Freshly prepared complement (Lowrestricted, and, like classical CTL, dependent on CD8' T Tox rabbit complement; Cedarlane Laboratories, Hornby, cells ( Fig. 2a and b) . When mice were immunized i.v. ""ith (Fig. 4) . As in the previous experiments, percent pulsed with p4ptidc 151-170 (A). cell, not exposed to any p5ptide specific lysis of LPf targets was great ere cent speciic (0), or P815 (H-2") cells pulsed with peptide 368-390 (3i).
this immunity is dependent on CD8* T cells, and CD8X CTL immunized with RLF. Regardless of the outcome of these clones against the CS protein and sporozoite surface protein studies, our data demonstrate the induction of CTL against 2 adoptively transfer protection against malaria. Thus, there the P. faicipaninz CS protein by immunization with soluble has been considerable work aimed at developing subunit protein without adjuvant. Since P. hIicipanmt does not vaccines that induce comparable protective CTL. This work infect mice, we cannot study the protective activity of these has primarily focused on the use of live recombinant vectors.
CTL. Nonetheless, this finding further opens the possibility However, the storage, delivery, and fielding, and in some for the development of soluble protein vaccines designed to cases even the production, of such vaccines would be much induce CTL against specific proteins. more difficult than would those of a vaccine that relied on synthetic peptide or recombinant protein. Work with peptides (2, 11, 16), which are by necessity limited in size to a ACKNOWLEDGMENTS small portion of any protein, and most recently with soluble
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